Auto-Renewal and Annual Lock-In: Subscribers who opt for the "discounted" $74/month annual plan report being unable to cancel mid-contract, even when they've stopped taking medication or experienced adverse side effects
No, you cant always file a claim, because lost money may not be enough
doi:10.1007/s11695-018-3525-0 Alberga AS, Edache IY, Forhan M, Russell-Mayhew S
As with all supplements, it depends on your individual needs and goals
New Egrifta WR formulation: Approved March 25, 2025 (tesamorelin F8, ready-to-use formulation) Active clinical trials: NAFLD/MASH (metabolic liver disease) and cognitive function studies ongoing Research-grade tesamorelin: Available for laboratory use separate from prescription Egrifta Researchers frequently ask about tesamorelin FDA approval status when investigating growth hormone-releasing hormone (GHRH) analogs
Frequently asked questions Is grey market tirzepatide the same molecule as Mounjaro or Zepbound